Section 1332 of the Patient Protection and Affordable Care Act (PPACA)
State Innovation Waivers – Reinsurance Waiver Quarterly Report

Reporting Instructions: Use the following template to capture data for quarterly 1332 waiver grant reporting, as specified in 45 CFR 155.1324(a), and referenced in your grant specific terms and conditions (STC). Quarterly reports are due 60 days following the end of each calendar quarter.

STATE: Maine

A. GRANTEE INFORMATION

1. Reporting Period End Date 03/31/2026			**2. Report Due Date** 5/31/2026
3. 1st Quarterly Report (●)	**2nd Quarterly Report** ( )	**3rd Quarterly Report** ( )	**4. Federal Agency and Organization Element to Which Report is Submitted** Consumer Information & Insurance Oversight (CCIIO)
5. Federal Grant Number Assigned by Federal Agency 1 SIWIW190005-01-00	**6a. DUNS Number** 160208815		**6b. EIN** 016000001
7. Recipient Organization Name State of Maine - Maine Guaranteed Access Reinsurance Association			
Address Line 1 254 Commercial Street			
Address Line 2			
Address Line 3			
City Portland	**State** ME		**Zip Code** 04101
Zip Extension			**8. Grant Period Start Date** Jan 1, 2019
9. Grant Period End Date 12/31/27 (Grant Period Extension approved 7/15/22)			
10. Other Attachments (attach other documents as needed or as instructed by the awarding Federal agency) None			

INFORMATION NOT RELEASABLE TO THE PUBLIC UNLESS AUTHORIZED BY LAW: This information has not been publicly disclosed and may be privileged and confidential. It is for internal government use only and must not be disseminated, distributed, or copied to persons not authorized to receive the information. Unauthorized disclosure may result in prosecution to the full extent of the law.

Section 1332 of the Patient Protection and Affordable Care Act (PPACA)
State Innovation Waivers – Reinsurance Waiver Quarterly Report

B. REPORT CERTIFICATION

11. Certification: I certify to the best of my knowledge and belief that this report is correct and complete for performance of activities for the purposes set forth in the award documents.

11a. Typed or printed name and title of Authorized Certifying Official	**11b. Signature of Authorized Certifying Official**
Christopher E. Howard Secretary, General Counsel Authorized Organizational Representative	Christopher E. Howard Digitally signed by Christopher E. Howard Date: 2026.05.20 11:26:50 -04'00'
11c. Telephone (area code, number, and extension) (207) 791-1335	**11d. E-mail address** choward@pierceatwood.com

11e. Date report submitted (month/day/year)

May 20, 2026

C. PROGRESS OF SECTION 1332 WAIVER - General

12. Provide an update on progress made in implementing and/or operating the approved 1332 waiver.

Consistent with prior years and expectations, there has been limited operational activity in Q1 due to the structure of the program as a retrospective model. Claims submissions for Q1 were predictably very light and not at all informative as regards overall 2026 results. The 2025 final claims submissions are not due until July 20, 2026.

MGARA's Section 1332 grant funding estimate has not been received and is not reported in Q1 results.

The proposed legislation increasing MGARA funding model was not enacted, so MGARA will continue with its historical assessment at $4 PMPM generating approximately $28 million in assessment revenue.

The MGARA Board has set 2027 reinsurance parameters at attachment points of $135,000 to $275,000 with a 65% coinsurance rate. At those parameters, early projections for 2027 show MGARA generating a loss of approximately $14 million resulting in MGARA drawing down $14 million of its surplus to apply to claims and expenses.

INFORMATION NOT RELEASABLE TO THE PUBLIC UNLESS AUTHORIZED BY LAW: This information has not been publicly disclosed and may be privileged and confidential. It is for internal government use only and must not be disseminated, distributed, or copied to persons not authorized to receive the information. Unauthorized disclosure may result in prosecution to the full extent of the law.

Section 1332 of the Patient Protection and Affordable Care Act (PPACA)
State Innovation Waivers – Reinsurance Waiver Quarterly Report

13. Describe any implementation and/or operational challenges, including plans for and results of associated corrective actions. After the first quarter, only report on changes and/or updates, as appropriate.

No operational challenges have been experienced in 2026 YTD. See response to Question 12 above.

INFORMATION NOT RELEASABLE TO THE PUBLIC UNLESS AUTHORIZED BY LAW: This information has not been publicly disclosed and may be privileged and confidential. It is for internal government use only and must not be disseminated, distributed, or copied to persons not authorized to receive the information. Unauthorized disclosure may result in prosecution to the full extent of the law.

Section 1332 of the Patient Protection and Affordable Care Act (PPACA)
State Innovation Waivers – Reinsurance Waiver Quarterly Report

D. POST-AWARD FORUM

(for Quarter Post-Award Forum was held)

14. Was the date, time, and location of the Post-Award Forum advertised 30 days in advance?

○ **Yes**

◉ **No**

15. State website address where Post-Award Forum was advertised

N/A

16. Date Post-Award Forum took place

The date for the 2026 Forum in process and notice will be published once the date is finalized.

17. Summary of Post-Award Forum, held in accordance with §155.1320(c), including all public comments received and actions taken in response to concerns or comments.

The Summary of Post-Award Forum will be provided with MGARA's Q2 2026 report.

18. Other Attachments (attach other documents as needed pertaining to Post-Award Form

None

INFORMATION NOT RELEASABLE TO THE PUBLIC UNLESS AUTHORIZED BY LAW: This information has not been publicly disclosed and may be privileged and confidential. It is for internal government use only and must not be disseminated, distributed, or copied to persons not authorized to receive the information. Unauthorized disclosure may result in prosecution to the full extent of the law.